|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 22, 16466-16472, June 2, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, October 15, 1999, and in revised form, March 6, 2000
IB1/JIP-1 is a scaffold protein that interacts
with upstream components of the c-Jun N-terminal kinase (JNK) signaling
pathway. IB1 is expressed at high levels in pancreatic IB1/JIP-1 are recently characterized mammalian scaffold proteins
involved in the regulation of the
JNK1 signaling pathway
(1-3). These two isoforms bind to and associate in a single
transduction complex three kinases, MLK3, MKK7, and JNK, which together
constitute an ordered unit of sequential signaling molecules
transducing a variety of stress signals (2, 3). To date, five different
isoforms of the protein have been cloned, which are mainly N-terminal
splice variants that arise from expression of one single gene on human
chromosome 11p11.2-p12 (1, 4, 5). A S59N mutation close to the JNK
binding domain of IB1 has recently been associated with a late onset
type 2 diabetes (6). Functionally, this mutation led to an increased
susceptibility of JNK-mediated apoptosis in different cell systems,
implying a presumably important functional role of IB1 in controlling
the cell response to proapoptotic stimuli (6).
Interleukin 1 (IL-1 This NO-dependent killing of To better understand the molecular mechanisms that specifically
sensitize Taken together, these data indicate that activation of the JNK pathway
certainly plays an important role in IL-1 Plasmids and Antibodies--
The IB1, FLAG-IB1,
JBD1-280 (amino acids 1-280 of IB1 (1, 2)), and FLAG-JBD
expressing vectors in the plasmid pBK (Stratagene) have been described
previously (1). Expression of the constructs was monitored by Western
blotting with anti-FLAG (Sigma) and anti-IB1 antibodies (1). The
pEGFP-N1 vector encoding the green fluorescent protein (GFP) was from
CLONTECH. This plasmid was modified by inserting a
FLAG sequence (Kodak) into the NheI site of the polylinker
in frame with the GFP. This FLAG sequence was designed to start with an
ATG embedded in a Kozack's consensus to allow for efficient
translation of the FLAG-GFP fusion protein (pEGFP-FLAG construct). The
constitutively active kinase domain of MEKK1,
Anti-IB1 antibodies raised against amino acids 1-280 of the protein
have been described (1). Anti-FLAG and anti-GST antibodies were from
Sigma and Upstate Biotechnology, respectively.
Cell Lines--
The insulin-secreting cell line Transfections--
3 × 105 cells were
transfected with plasmids in 3-cm dishes using DOTAP (Roche Molecular
Biochemicals) following instructions from the manufacturer. For
experiments involving GAL-Jun (amino acids 1-89), GAL-ATF2 (amino
acids 1-96), and GAL-Elk1 (amino acids 307-428) (all from
Stratagene), 20 ng of each of these plasmids were transfected with 1 µg of the reporter plasmid pFR-Luc (containing five repeats of the
GAL4 DNA binding site, Stratagene) and 0.5 µg of Whole Cell Lysate and Solid Phase JNK Assay--
Cellular
extracts were prepared by scraping cells in lysis buffer (20 mM Tris acetate, 1 mM EGTA, 1% Triton X-100,
10 mM p-nitrophenyl-phosphate, 5 mM
sodium pyrophosphate, 10 mM
For the JNK solid phase assays, extracts were incubated for 1 h at
room temperature with 1 µg of GST-Jun and 10 µl of
glutathione-agarose beads (Sigma). Following four washes with the
scraping buffer, the beads were resuspended in the same buffer
supplemented with 10 mM MgCl2 and 5 µCi of
[ Nitric Oxide Secretion--
NO released in the cell medium was
measured using the Griess reagent (Alexis). INS-1 CTR1 and AS7 cells
were incubated for 16 h with doxycycline (200 ng/ml) and then
cultured for two days in the presence of IL-1 Statistics--
Results are presented as mean ± S.E.
or ± S.D. (for n = 2). Data were analyzed with a
Wilcoxon's test.
Cytokines, Low Glucose, UV Light, and
To determine whether other JNK activators could decrease IB1 levels, we
treated cells with UV light or incubated them in a low glucose medium
(0.5 mM glucose) (36, 37). We also co-transfected cells
with expression vectors encoding the activated form of the upstream JNK
activator IB1 Prevented Cytokine and
To determine whether overexpression of IB1 could prevent IL-1 IB1 Decreased JNK-mediated Activation of c-Jun, ATF2, and
Elk1--
The effects of JNK on gene transcription are accomplished
via the phosphorylation of the trans-acting
domains of different transcription factors including c-Jun, ATF2, and
Elk1, an event resulting in an increased transcriptional activity. To
demonstrate activation of MAP kinases by IL-1
To study the regulation of JNK signaling by IB1 in INS-1 AS7 Cells Expressing a Doxycycline Inducible IB1 Antisense
RNA Had Increased Apoptotic Rates in Response to IL-1 INS-1 AS7 Cells Do Not Release More NO in Presence of Doxycycline
and Cytokines--
Nitric oxide production in response to IL-1 INS-1 AS7 Cells Showed Higher Phosphorylation of c-Jun in Response
to Doxycycline and Cytokines--
To determine whether the increased
apoptotic rate observed in the INS-1 AS7 was associated with a
differential ability of JNK to activate c-Jun, we performed solid phase
JNK assays. Cells were treated with IL-1 We showed herein that stress events decrease IB1 levels in
insulin-producing cells. Our results using a cell line expressing IB1
antisense RNA indicate that this single event sensitizes cells to
IL-1 The absence of increased NO production in response to IL-1 Our results indicate that IB1 plays an important role in limiting the
effects of JNK signaling on the fate of insulin-producing cells. Three
lines of evidences support this conclusion. First, decreasing IB1
levels with an antisense RNA sensitizes the INS AS7 cells to
IL-1 IB1/JIP-1 binds three kinases, MLK3, MKK7, and JNK, which together
constitute an ordered three-partite signaling module leading to
activation of JNK. We described IB1 as being localized in both the
nucleus and cytoplasm of pancreatic Our data indicate that the near absence of c-Jun and ATF2 activation at
late time points (3-6 h of IL-1 The critical role of IL-1 We are grateful to Christian Widmann for the
generous gift of the *
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by Grants 32-54119.98 and 32-49673.96 from the Swiss
National Foundation for Scientific Research, the Placide Nicod Foundation, and the Botnar Foundation.
¶
To whom correspondence should be addressed. Tel.:
41-21-314-33-79; Fax: 41-21-314-33-85; E-mail:
christophe.bonny@chuv.hospvd.ch.
Published, JBC Papers in Press, March 10, 2000, DOI 10.1074/jbc.M908297199
2
A. Ammendrup, A. Oberson, K. Nielsen, N. Andersen, P. Serup, O. Madsen, T. Mandrup-Poulsen, and C. Bonny,
submitted for publication.
3
A. Oberson and C. Bonny, unpublished data.
The abbreviations used are:
JNK, c-Jun
N-terminal kinase;
IL, interleukin;
iNOS, inducible nitric-oxide
synthase;
MAP, mitogen-activated protein;
MEKK1, MAP
kinase/extracellular signal-regulated kinase kinase kinase 1;
JBD, JNK
binding domain;
GFP, green fluorescent protein;
GST, glutathione
S-transferase;
TNF, tumor necrosis factor;
IFN, interferon.
IB1 Reduces Cytokine-induced Apoptosis of Insulin-secreting
Cells*
§¶,
,
,
,
, and
Division of Medical Genetics and the
Department of Internal Medicine, CHUV University Hospital,
1011 Lausanne Switzerland
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
cells and
may therefore exert a tight control on signaling events mediated by JNK
in these cells. Activation of JNK by interleukin 1 (IL-1
) or by the
upstream JNK constitutive activator
MEKK1 promoted apoptosis in two
pancreatic
cell lines and decreased IB1 content by 50-60%. To
study the functional consequences of the reduced IB1 content in
cell lines, we used an insulin-secreting cell line expressing an
inducible IB1 antisense RNA that lead to a 38% IB1 decrease. Reducing
IB1 levels in these cells increased phosphorylation of c-Jun and
increased the apoptotic rate in presence of IL-1
. Nitric oxide
production was not stimulated by expression of the IB1 antisense RNA.
Complementary experiments indicated that overexpression of IB1 in
insulin-producing cells prevented JNK-mediated activation of the
transcription factors c-Jun, ATF2, and Elk1 and decreased IL-1
- and
MEKK1-induced apoptosis. These data indicate that IB1 plays an
anti-apoptotic function in insulin-producing cells probably by
controlling the activity of the JNK signaling pathway.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
), which activates JNK essentially through the
MKK7 pathway in several cells and tissues (7-10), is believed to play
a key role in the process of selective
cell destruction observed in
type 1 diabetes. Chronic exposure of pancreatic islets or of
-derived cell lines to IL-1
had been shown to lead to the
selective death of the
cells, whereas non-
cells such as glucagon-producing cells appeared more resistant to the action of the
cytokine (reviewed in Refs. 11-15). The molecular basis for the
preferential killing of pancreatic
versus
cells by IL-1
is not fully understood. One important player in this
phenomenon is the inducible nitric-oxide synthase gene iNOS, which is
specifically expressed in the
cells upon IL-1
treatment
(16-20). A number of reports have indeed clearly shown that
cell
apoptosis is NO-dependent (see for example two recent
reports (21, 22)). In line with this, pancreatic islets from iNOS KO
mice show a better resistance to IL-1
cytotoxicity (23).
cells has been, however,
challenged by several reports pointing to the existence of
NO-independent death signaling pathways (24, 25). For example, there is
no direct correlation between expression of iNOS and sensitivity to
IL-1
between
cells at different stages of differentiation (26).
Importantly, the iNOS inhibitor L-NMMA does not prevent IL-1
-induced
cell death in rat or human islets (24, 25). It is
also possible to block NO synthesis by blocking the extracellular signal-regulated kinase and p38 MAP kinase pathways, however, without
any positive effect on cell survival (17).
cells to IL-1
-induced death, we recently used two
different subclones of the pluripotent pancreatic endocrine stem cell
clone (MSL). The MSL AN697C1 subclone gave rise to two derived cell
lines, namely the glucagon-secreting AN-glu, and after stable
transfection with the transcription factor pancreatic duodenal homeobox
factor-1, the insulin secreting AN-ins (27). Despite having similar
rates of NO synthesis, we found that the AN-ins cells were more
susceptible to apoptosis elicited by IL-1
. The AN-ins cells show a
markedly increased activation of JNK in response to IL-1
, thus
providing a molecular basis for the observed difference in their
IL-1
sensitivity. In these cell systems, we demonstrated that the
two MAP kinases p38 and the extracellular signal-regulated kinase were
fully dispensable to promote the apoptotic response. In contrast, JNK
activation is essential as blocking JNK with the use of the JNK binding
domain (JBD) of JIP-1/IB1 (2) prevented apoptosis by more than
90%.2 Not only did JBD
prevent apoptosis, but also a significant fraction of cells exposed to
the cytokine were able to retain their ability to divide in
culture.2
-mediated apoptosis.
Because IL-1
is known to activate JNK through MKK7 in different cell
lines and tissues (7-10) and because both kinases interact with the
scaffold protein IB1, these data suggest that the control of the
MKK7-JNK signaling pathway by IB1 may interfere with the response of
cells activated by IL-1
. In this report, we specifically examined
the role of IB1 in IL-1
-induced apoptosis in pancreatic
cell lines.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MEKK1, was cloned into
the expression vector pCDNA3 (Invitrogen) (28).
TC-3 (29) was
cultured in RPMI 1640 medium (11.1 mM glucose) supplemented
with 10% fetal calf serum, 100 µg/ml streptomycin, 100 units/ml
penicillin, and 2 mM glutamine. The INS-1 CTR1 and AS7 cell
clones (6, 30) were cultured in the same medium supplemented with 50 mM
-mercaptoethanol (31). The INS-1 AS7 cells express
IB1 antisense RNA under the control of a tetracycline regulatable
promoter. The addition of doxycycline (200 ng/ml) leads to full
expression of the antisense RNA and to a 38% decrease in IB1 protein
content (6). INS-1 CTR1 do not express a transgene construct. The cell
line INS-1 appeared more resistant to the cytotoxic activity of IL-1
than the
TC-3 cells. Therefore, we potentiated the action of IL-1
in INS-1 by the addition of TNF-
and IFN-
(32). IL-1
(2 × 105 units/µg, Alexis) was used at a concentration of
10 ng/ml (TNF-
(105 units/µg, Alexis) at a
concentration of 10 ng/ml and IFN-
(Alexis) at a concentration of
100 units/ml).
MEKK1 for 24 h. The luciferase activities were measured using the "Dual Reporter
System" from Promega. To evaluate the number of apoptotic cells, the
pEGFP-FLAG vector (0.5 µg) was added to each transfection to identify
transfected cells. Cells were then observed under an inverted
fluorescence microscope (Zeiss, Axiovert 25). Apoptotic cells were
discriminated from normal cells by the characteristic "blebbing" of
the cytoplasm, easily determined from the fluorescence emitted by the
GFP. For experiments involving the INS-1 CTR1 and AS7 clones (6), cells
were incubated with Hoechst 33342 and propidium iodide (33) for 7 min
before visualization under the inverted fluorescent microscope. A
minimum of 1000 cells in duplicate was counted for each experiment.
-glycerophosphate, 1 mM dithiothreitol). Debris were removed by centrifugation
for 5 min at 15,000 rpm in a SS-34 rotor (Beckman). One µg of GST-Jun
(amino acids 1-89), GST-ATF2 (amino acids 1-96), or GST-Elk1 (amino
acids 307-428) was then added to 100 µg of cellular extracts
supplemented with 10 mM MgCl2 and 5 µCi of
[
-33P]ATP. Following incubation at 30 °C for 20 min, reaction products were separated by SDS-polyacrylamide gel
electrophoresis on a denaturing 10% polyacrylamide gel. The gels were
dried, stained with Coomassie Blue to check for equal loading of the
samples, and subsequently exposed to x-ray film (Kodak).
-33P]ATP. Following incubation at 30 °C for 30 min, extracts were processed as before. In INS-1 and
TC-3 cells, we
observed that maximal JNK activity occurred between 1 and 3 h of
treatment with IL-1
(10 ng/ml). Therefore, we prepared extracts
after time points at 1, 3, and 6 h following IL-1
treatment.
, TNF-
, and IFN-
before NO release was evaluated. 500 µl of medium was then combined
with 500 µl of Griess reagent, and absorbance values (550 nm) were
read 10 min later.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MEKK1 Decreased IB1
Content--
JNK regulates the stability of its associated
transcription factors by targeting them to ubiquitination and
proteolytic degradation (34, 35). To determine whether the JNK
activator IL-1
could modulate IB1 content, we performed Western blot
analyses of
TC-3 and INS-1 cellular extracts treated with IL-1
for two days. Compared with control
TC-3 cells, IL-1
induced a
55% decreased IB1 content normalized to
-tubulin. Similarly, a
combination of IL-1
, TNF-
, and IFN-
induced a 52% decrease in
normalized IB1 content in INS-1 cells (Fig.
1A). IL-1
and TNF-
only
weakly decreased IB1 content in this cell line (Fig. 1B).
The combination of all three cytokines was chosen because we found that
neither cytokine alone induced significant apoptosis in this cell line
(32).

View larger version (15K):
[in a new window]
Fig. 1.
IL-1
and
MEKK1 decrease IB1 content. A,
TC-3
cells were treated with IL-1
and INS-1 cells were treated with
IL-1
/TNF-
/IFN-
for two days. Cells were then resuspended in
SDS-loading buffer and analyzed by SDS-polyacrylamide gel
electrophoresis and Western blotting with the indicated antibodies.
-Tub, anti-tubuline antibody;
-IB1,
anti-IB1 antibody (1);
, untreated cells; +, cytokine-treated cells;
cyt, cytokines. B, quantification of IB1 decrease
in INS-1 cells treated with different cytokines. INS-1 cells were
treated with IL-1
, TNF
, or IFN
alone or in combination for
48 h. Cells were then processed as in A with
normalization performed using antibodies against
-tubulin. The ratio
of IB1/tub in control condition is set to 100. Note that only a
combination of the three cytokines induce significant apoptosis in this
cell line. n = 3, only the decrease in presence of all
three cytokines is statistically significant (p < 0.05). C, quantification of IB1 decrease in
TC-3 cells
under different stress conditions. Control (CTRL) and
IL-1
-treated cells were processed as in A. Other
treatments: 0.5 mM glucose, cells were incubated
at 0.5 mM glucose for two days; UV, cells were
exposed to 20 J/m2 UV light (Stratalinker, Stratagene) and
were processed 1 h later;
MEKK1, cells were
co-transfected with pcDNA3.1 or
MEKK1 and the pEGFP-FLAG vector
for normalization for 24 h. Blots were then exposed to either
anti-IB1 and anti-tubuline antibodies (CTRL, IL-1
, and 0.5 mM glucose samples) or to anti-IB1 and anti-FLAG antibodies
(
MEKK1). Following densitometric scanning of the blots, the ratio of
IB1/tub or IB1/FLAG was calculated (normalized IB1 content (%)). The
ratio of IB1/tub in control condition is set to 100. n = 3-5 for each experimental conditions, p values relative
to CTRL are below 0.05.
MEKK1 (28), together with the pEGFP-FLAG vector used as an
internal standard to normalize for transfection efficiencies. Compared
with cells in control conditions, UV light decreased IB1 levels by
68%, low glucose treatments lowered IB1 by 73%, and
MEKK1
decreased IB1 by 67% (Fig. 1C).
MEKK1-induced Apoptosis--
We
evaluated the number of apoptotic
cells with a combination of
propidium iodide and Hoechst 33342 nuclear staining as described
previously (33). This combination of dyes allows for the differential
staining of necrotic, apoptotic, and live nuclei (33). Two days of
culture in the presence of IL-1
(10 ng/ml) induced a 3.5-fold
increased apoptotic rate in
TC-3 cells (Fig. 2). Transfection with
MEKK1, a strong
activator of the MAP kinase kinase MKK4 (also termed JNK kinase 1),
promoted a strong apoptotic response from 3.3 ± 1.1% to
23.1 ± 4.8% in control and
MEKK1 transfected cells,
respectively (Fig. 2). This rate of apoptosis appeared similar to the
one previously reported for other non-
cell lines (38).

View larger version (18K):
[in a new window]
Fig. 2.
IB1 decreases IL-1
-
and
MEKK1-induced apoptosis. Cells were
transfected with pEGFP-FLAG, and the indicated vectors were transfected
for either 16 (
MEKK1) or 48 h (IL-1
). Apoptotic cells were
then counted. A minimum of 1000 transfected cells were counted in five
separate experiments. p < 0.01 for IL-1
and
MEKK1 conditions relative to CTRL. p < 0.01 for
IL1-
/IB1 and
MEKK1/IB1 conditions relative to IL-1
and
MEKK1, respectively
- or
MEKK1-induced apoptosis, we transfected
TC-3 cells with vectors
expressing the IB1 protein (1). In these experiments, cells were
co-transfected with an expression vector encoding the green fluorescent
protein (pEGFP-FLAG). Following transfection, cells were incubated with
10 ng/ml IL-1
for two days, and apoptotic cells were counted. We
noted that IB1 had a small but reproducible "survival" effect on
cells in control conditions lowering the apoptotic rate by 0.5-1%
(data not shown). Furthermore, overexpression of IB1 reduced
IL-1
-induced apoptosis by 80% (Fig. 2). We observed similar
protection with the INS-1 cell line activated by a combination of
IL-1
/TNF-
/IFN-
(data not shown). IB1 also decreased apoptosis promoted by
MEKK1 (Fig. 2). Similar protection was also observed with the JBD only of IB1/JIP-1 (data not shown).2
in the
insulin-secreting cell line
TC-3, we first performed in
vitro kinase assays in whole cell lysates using as substrate
GST-Jun (a substrate for JNK only), GST-ATF2 (phosphorylated by JNK and
p38), and GST-Elk1 (phosphorylated by JNK and extracellular
signal-regulated kinase 1/2). Kinase activity toward all three fusion
proteins was detected in control cells (0', Fig.
3A). IL-1
weakly enhanced
phosphorylation of c-Jun, whereas ATF2 was strongly activated after
1 h of treatment, and Elk1 activation appeared to be more
persistent. To specifically determine whether IL-1
activated JNK, we
performed a solid phase assay using GST-Jun as substrate. We observed a
strong and persistent activation of JNK after exposure to IL-1
,
peaking at 1-3 h and declining at 16 h (Fig. 3B).

View larger version (19K):
[in a new window]
Fig. 3.
Persistent activation of JNK in
TC-3 cells by IL-1
.
A, top, whole cell lysate kinase assays using
GST-Jun, GST-ATF2, and GST-Elk1 as substrate. Whole cell extracts were
prepared from
TC-3 cells as described under "Materials and
Methods." Times of exposure with IL-1
are indicated. One half of
the reaction was loaded on a polyacrylamide gel, and
-33P-phosphorylation of the substrates (P-GSTs) was
subsequently analyzed with an InstantImager Apparatus (Perkin-Elmer).
Bottom, the other half of the reaction was analyzed by
Western blotting with anti-GST antibodies (
-GSTs) to show equal
loading of the samples. B, solid phase JNK assays. JNK was
first purified using GST-Jun, and then kinase assays were performed.
-33P-Phosphorylated substrates were separated on a
polyacrylamide gel that was analyzed with an InstantImager Apparatus
(Perkin-Elmer). Samples were processed as in A.
TC-3 cells, we
used a heterologous GAL4 reporter system in which the GAL4 DNA binding
domain was linked to the transactivation domains of c-Jun, ATF2, or
Elk1. As shown in Fig. 4A,
IL-1
induced a weak activation of ATF2 and Elk1 in
TC-3 cells
that could be blocked by overexpression of IB1. To more potently
activate JNK, we transfected cells with
MEKK1. This lead to a strong
activation of Elk1 (>50-fold, Fig. 4B). Surprisingly,
MEKK1 activated c-Jun and ATF2 only modestly (6-8-fold). These low
levels of c-Jun and ATF2 activation appeared specific to the
cell
lines used, as control experiments employing HeLa and Swiss 3T3 cells
gave a similar high level of activation of the three transcription
factors (about
50-100-fold).3 However,
co-transfection with vectors encoding IB1 prevented activation of the
three transcription factors, an effect consistent with the one observed
with the JBD alone of IB1 (2) (Fig. 4B).

View larger version (17K):
[in a new window]
Fig. 4.
Activation of JNK by IL-1
and
MEKK1 in a luciferase reporter
assay. A,
TC-3 cells were transfected with the
5xGAL-luciferase reporter vector and constructs expressing the
indicated factors. Empty vectors were added when necessary. IL-1
(10 ng/ml) was added 3 h following transfections as indicated. After
16 h, cell extracts were recovered and normalized to protein
content, and luciferase activities were measured. The activities of the
GAL-Elk1, GAL-Jun, and GAL-ATF2 constructs in the absence of IL-1
-
and IB1-expressing plasmids are set to 100. n = 3, p < 0.05 for ATF2/IL-1
and Elk1/IL-1
conditions
relative to ATF2 and Elk1, respectively. p < 0.05 for
ATF2/IL-1
/IB1 and Elk1/IL-1
/IB1 conditions relative to
ATF2/IL-1
and Elk1/IL-1
. B,
TC-3 cells were
transfected with the 5xGAL-luciferase reporter vector and constructs
expressing the indicated factors. Empty vectors were added when
necessary. After 16 h, cell extracts were processed as described
in A. The activities of the GAL-Elk1, GAL-Jun, and GAL-ATF2
constructs in the absence of
MEKK1- and IB1-expressing plasmids are
set to 100. n = 5-7, p < 0.01 for all
MEKK1 conditions relative to controls. p < 0.01 for
all
MEKK1/IB1 conditions relative to IL-1
. RLU,
relative light units (arbitrary units).
--
To
determine whether the high endogenous IB1 content in
cells
interfered with the apoptotic response, we used the insulin-secreting INS-1 clone AS7 previously described (6). This cell clone expresses IB1
antisense RNA under the control of a doxycycline inducible promoter
leading to a 38% decrease in IB1 content. The cell clone INS-1 CTR1
was used here as a control (6). In pilot experiments, we observed that
INS-1 cells were relatively resistant to the action of IL-1
, so that
a combination of IL-1
, TNF-
, and IFN-
was then used to promote
significant apoptosis (32). At day 1, cells were seeded on plates, and
expression of the IB1 antisense RNA was induced by doxycycline (200 ng/ml). 24 h later, IL-1
, TNF-
, and IFN-
were added, and
cells were incubated for a further 48 h. The number of apoptotic
cells was then evaluated. INS-1 AS7 and INS-1 CTR1 cells have a basal
apoptotic rate of 1.5-2%, which is increased to 17-19% in the
presence of IL-1
/TNF-
/IFN-
. Doxycycline had no effect on the
control INS-1 CTR1 cells in presence or absence of
IL-1
/TNF-
/IFN-
. However, expression of the IB1 antisense RNA
in the INS-1 AS7 cell line more than doubled the apoptotic rate in the
presence of IL-1
(Fig. 5).

View larger version (20K):
[in a new window]
Fig. 5.
Reducing IB1 levels in the INS-1 AS7 cells
increases the apoptotic rate induced by
IL-1
/TNF-
/IFN-
.
INS-1 CTR1 and AS7 cells were treated with doxycycline (Dox,
200 ng/ml) or not for 16 h, and then IL-1
/TNF-
/IFN-
was
added or not for two days. Cells were finally stained with Hoechst
33342 and propidium iodide and counted. The ratio of apoptotic to
normal cells is indicated. n = 10, p < 0.01 for all cytokines treated; conditions are relative to controls.
p < 0.01 for AS7/Dox/cytokines; conditions are
relative to AS7/cytokines
participates to the apoptotic response of the INS-1 cell line (39). We
therefore measured NO production in INS-1 CTR1 and AS7 cells that had
been treated or not with IL-1
/TNF-
/IFN-
and doxycycline. As
shown in Fig. 6, the decrease in IB1
content induced by doxycycline in AS7 cells did not lead to an
increased NO production in response to the cytokines.

View larger version (22K):
[in a new window]
Fig. 6.
No increase in NO production in INS AS7 cells
expressing IB1 antisense RNA. INS-1 CTR1 and AS7 cells were
pretreated or not with doxycycline (Dox, 200 ng/ml) for
16 h before IL-1
was added. NO release was measured 48 h
later using a Griess reagent. n = 6, p < 0.01 for cytokines conditions relative to controls.
/TNF-
/IFN-
in the
presence/absence of doxycycline for various times, and JNK was pulled
down using GST-Jun. As shown in Fig. 7,
JNK from the INS-1 AS7 cells in the presence of doxycycline (200 ng/ml)
was more active in phosphorylating c-Jun during the initial phase of
the response to IL-1
/TNF-
/IFN-
(3.8-fold increase in the
presence of doxycycline compared with 2.1-fold in its absence after
1 h). It is not clear from these experiments 1) whether the
observed increased c-Jun phosphorylation resulted from an actual
increase in JNK activity or 2) whether it resulted from a higher JNK
availability in the assay that would be secondary to the lower IB1
content.

View larger version (21K):
[in a new window]
Fig. 7.
INS-1 AS7 cells show a more pronounced JNK
activation in response to
IL-1
/TNF-
/IFN-
.
INS-1 AS7 cells were treated (black bars) or not
(empty bars) with doxycycline (Dox, 200 ng/ml)
for 16 h and were subsequently incubated with
IL-1
/TNF-
/IFN-
for 1 h. Cell extracts were then prepared,
and JNK kinase assays were performed. Gels were analyzed with an
InstantImager Apparatus (Perkin-Elmer). Bars show the extent
of c-Jun phosphorylation over basal levels (no cytokines, no
doxycycline) from two independent experiments. Standard deviations are
indicated. p < 0.05.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-induced apoptosis without an increase in NO synthesis. Because
IL-1
is recognized as one of the key mediators of pancreatic
cell apoptosis in type 1 diabetes, we propose that the high amount of
IB1 normally present in insulin-producing cells is a critical parameter
that preserves cells from cytokine-induced destruction (Fig.
8).

View larger version (37K):
[in a new window]
Fig. 8.
Possible regulatory role of IB1 in
pancreatic
cells. A, high amount
of IB1 may bind most of the JNKs available in a cell. Because IB1
interacts ~100-fold more tightly with JNK than does c-Jun or ATF2
(2), IB1 would in such a situation prevent c-Jun and ATF2, but not
Elk1, from interacting with JNK. Therefore, most of the JNK activity
would be directed toward Elk1. B, in the absence of IB1, JNK
is free to interact with c-Jun, ATF2, and Elk1. The model implies that
pancreatic
cells activated by IL-1
gradually pass from the
situation in "A" to the one in "B"
therefore allowing for the recruitment of c-Jun and ATF2. These events
would then facilitate apoptosis.
in the
INS-1 AS7 relative to INS-1 CTR1 cells indicates that activation of
other pathways is responsible for the higher apoptotic rate of this
cell line. This does not preclude NO as a necessary mediator of
apoptosis in this cell system. Indeed, INS-1 cells have been shown to
be protected from the deleterious effects of IL-
by the iNOS
inhibitor L-NMMA (39). Rather, these and previous data indicate that NO is not the only player mediating
cell apoptosis and that independent activation of JNK is also required.2
In this sense, endogenous regulators of JNK may play a specific role in
the development of
cell apoptosis.
-induced apoptosis (Fig. 5). This effect is likely to result
from an increased ability of JNK to phosphorylate its substrates
including c-Jun (Fig. 7). Second, overexpression of IB1 protects
pancreatic
cell lines against the two proapoptotic stimuli IL-1
and
MEKK1 (Fig. 2). This effect correlates with the ability of IB1
to block JNK-mediated activation of c-Jun and ATF2 (Fig. 4,
A and B). Third, we found a correlation in INS-1 cells between the decrease in IB1 levels and the proapoptotic potential
of the three cytokines IL-1
, TNF-
, and IFN-
alone or in
combination (Fig. 1B).
cells (1). Because IB1 is
expressed at very high levels in pancreatic
cells compared with
most other cell types, the high amount of IB1 in pancreatic
cells
may exert a very stringent control on JNK signaling. High levels of IB1
may be expected to have negative effects on the ability of the JNK
cascade to transmit signaling (2, 3, 5), and in
cells, this may be
accounted for by two distinct mechanisms. First, high amounts of IB1
may have a "dispersive" effect by favoring the formation of
incomplete, nonproductive signaling complexes (i.e.
complexes lacking either one of the three kinases that normally
transmit signaling) (2, 3). This situation occurs in experimental
conditions like the transfection studies used in this study and as a
result leads to uncoupling of JNK from its upstream activators MKK7 and
MLK3. This leads to inefficient JNK activation that translates into low
c-Jun, ATF2, or Elk1 phosphorylation (5). Second, IB1 may have a
"competitive" effect in the nucleus acting against the binding of
c-Jun and ATF2 to JNK. This hypothesis is supported by the observation
that IB1/JIP-1 binds ~100-fold more tightly to the same domain of JNK than does c-Jun or ATF2 (2). In conditions where most of the JNKs
available in a cell would be bound to IB1, c-Jun and ATF2 would be
efficiently prevented to interact with and to be activated by JNK. As a
consequence, high amounts of IB1 may "route" JNK signaling toward
factors, such as Elk1 that do not use a "JNK binding domain"
similar to that of c-Jun, ATF2, or IB1 to become substrate of JNK (40,
41).
, Fig. 3A) in whole cell
lysates occurs despite a robust activation of JNK (Fig. 3B). There is thus dissociation between JNK activation and c-Jun and ATF2
phosphorylation in these cells. Transient transfection experiments employing
MEKK1 indicate that only Elk1 is strongly activated by
JNK, in contrast to c-Jun and ATF2 (Fig. 4B). In control
experiments performed with HeLa and Swiss 3T3 cells (which express only
minute amounts of IB1), activation of the three factors reached similar high levels.3 Therefore in pancreatic
cells, JNK
signaling appears to be "routed" preferentially toward Elk1
activation, and our data indicate that IB1 may play a role in this
process (Figs. 4B and 7). The selective activation of Elk1
in detriment to c-Jun and ATF2 is presumably not sufficient to induce
apoptosis (42). If the model holds true, the observed IB1 decrease
following JNK stimulation is therefore likely to represent an important
control step to allow for the apoptotic response to develop (Fig. 8).
The mechanisms by which the stability of IB1 is regulated by JNK is not
known yet, but we may speculate that it involves a
phosphorylation-dependent ubiquitination process, as
observed with other JNK targets (34, 35).
as mediator of pancreatic
cell death
in type 1 diabetes is well recognized (12, 14). Our data have
demonstrated the essential role that activation of the JNK pathway
plays in IL-1
-induced
cell apoptosis.2 The
intracellular events that transmit IL-1
signaling involve the
sequential activation of the two kinases MKK7 and JNK (7-9). These
kinases are held together in a multiple protein complex by the scaffold
protein IB1. Here, we have established that high expression of this
scaffold protein in pancreatic
cells limits the output of JNK
signaling toward apoptosis induced by IL-1
. As this protective
effect may be attenuated following the observed decrease of IB1 in
IL-1
-treated cells, our results may lead to therapeutic strategies
aimed at preserving IB1 function in pancreatic
cells.
![]()
ACKNOWLEDGEMENT
MEKK1 expressing plasmid and for helpful discussions.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Bonny, C.,
Nicod, P.,
and Waeber, G.
(1998)
J. Biol. Chem.
273,
1843-1846
2.
Dickens, M.,
Rogers, J. S.,
Cavanagh, J.,
Raitano, A.,
Xia, Z.,
Halpern, J. R.,
Greenberg, M. E.,
Sawyers, C. L.,
and Davis, R. J.
(1997)
Science
277,
693-696
3.
Whitmarsh, A. J.,
Cavanagh, J.,
Tournier, C.,
Yasuda, J.,
and Davis, R. J.
(1998)
Science
281,
1671-1674
4.
Mooser, V.,
Maillard, A.,
Bonny, C.,
Steinmann, M.,
Shaw, P.,
Yarnall, D. P.,
Burns, D. K.,
Schorderet, D. F.,
Nicod, P.,
and Waeber, G.
(1999)
Genomics
55,
202-208
5.
Kim, I. J.,
Lee, K. W.,
Park, B. Y.,
Lee, J. K.,
Park, J.,
Choi, I. Y.,
Eom, S. J.,
Chang, T. S.,
Kim, M. J.,
Yeom, Y. I.,
Chang, S. K.,
Lee, Y. D.,
Choi, E. J.,
and Han, P. L.
(1999)
J. Neurochem.
72,
1335-1343
6.
Waeber, G.,
Delplanque, J.,
Bonny, C.,
Mooser, V.,
Steinmann, M.,
Widmann, C.,
Maillard, A.,
Miklossy, J.,
Dina, C.,
Hani, E. H.,
Vionnet, N.,
Nicod, P.,
Boutin, P.,
and Froguel, P.
(2000)
Nat. Genet.
24,
291-295
7.
Cuenda, A.,
and Dorow, D. S.
(1998)
Biochem. J.
333,
11-15
8.
Finch, A.,
Holland, P.,
Cooper, J.,
Saklatvala, J.,
and Kracht, M.
(1997)
FEBS Lett.
418,
144-148
9.
Lawler, S.,
Cuenda, A.,
Goedert, M.,
and Cohen, P.
(1997)
FEBS Lett.
414,
153-158
10.
Whitmarsh, A. J.,
Shore, P.,
Sharrocks, A. D.,
and Davis, R. J.
(1995)
Science
269,
403-407
11.
Mauricio, D.,
and Mandrup-Poulsen, T.
(1998)
Diabetes
47,
1537-1543
12.
Mandrup-Poulsen, T.
(1996)
Diabetologia
39,
1005-1029
13.
Nerup, J.,
Mandrup-Poulsen, T.,
Helqvist, S.,
Andersen, H. U.,
Pociot, F.,
Reimers, J. I.,
Cuartero, B. G.,
Karlsen, A. E.,
Bjerre, U.,
and Lorenzen, T.
(1994)
Diabetologia
37 Suppl. 2,
82-89
14.
Mandrup-Poulsen, T.,
Zumsteg, U.,
Reimers, J.,
Pociot, F.,
Morch, L.,
Helqvist, S.,
Dinarello, C. A.,
and Nerup, J.
(1993)
Cytokine
5,
185-191
15.
Rabinovitch, A.,
and Suarez-Pinzon, W. L.
(1998)
Biochem. Pharmacol.
55,
1139-1149
16.
Heitmeier, M. R.,
Scarim, A. L.,
and Corbett, J. A.
(1997)
J. Biol. Chem.
272,
13697-13704
17.
Larsen, C. M.,
Wadt, K. A.,
Juhl, L. F.,
Andersen, H. U.,
Karlsen, A. E.,
Su, M. S.,
Seedorf, K.,
Shapiro, L.,
Dinarello, C. A.,
and Mandrup-Poulsen, T.
(1998)
J. Biol. Chem.
273,
15294-15300
18.
Reimers, J. I.,
Bjerre, U.,
Mandrup-Poulsen, T.,
and Nerup, J.
(1994)
Cytokine
6,
512-520
19.
Reimers, J. I.,
Andersen, H. U.,
Mauricio, D.,
Pociot, F.,
Karlsen, A. E.,
Petersen, J. S.,
Mandrup-Poulsen, T.,
and Nerup, J.
(1996)
Diabetes
45,
771-778
20.
Cetkovic-Cvrlje, M.,
and Eizirik, D. L.
(1994)
Cytokine
6,
399-406
21.
Thomas, H. E.,
Darwiche, R.,
Corbett, J. A.,
and Kay, T. W.
(1999)
J. Immunol.
163,
1562-1569
22.
Grey, S. T.,
Arvelo, M. B.,
Hasenkamp, W.,
Bach, F. H.,
and Ferran, C.
(1999)
J. Exp. Med.
190,
1135-1146
23.
Flodstrom, M.,
Tyrberg, B.,
Eizirik, D. L.,
and Sandler, S.
(1999)
Diabetes
48,
706-713
24.
Delaney, C. A.,
Pavlovic, D.,
Hoorens, A.,
Pipeleers, D. G.,
and Eizirik, D. L.
(1997)
Endocrinology
138,
2610-2614
25.
Suarez-Pinzon, W. L.,
Strynadka, K.,
and Rabinovitch, A.
(1996)
Endocrinology
137,
5290-5296
26.
Nielsen, K.,
Karlsen, A. E.,
Deckert, M.,
Madsen, O. D.,
Serup, P.,
Mandrup-Poulsen, T.,
and Nerup, J.
(1999)
Diabetes
48,
2324-2332
27.
Serup, P.,
Jensen, J.,
Andersen, F. G.,
Jorgensen, M. C.,
Blume, N.,
Holst, J. J.,
and Madsen, O. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9015-9020
28.
Widmann, C.,
Johnson, N. L.,
Gardner, A. M.,
Smith, R. J.,
and Johnson, G. L.
(1997)
Oncogene
15,
2439-2447
29.
Efrat, S.,
Linde, S.,
Kofod, H.,
Spector, D.,
Delannoy, M.,
Grant, S.,
Hanahan, D.,
and Baekkeskov, S.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9037-9041
30.
Wang, H.,
Maechler, P.,
Hagenfeldt, K. A.,
and Wollheim, C. B.
(1998)
EMBO J.
17,
6701-6713
31.
Asfari, M.,
Janjic, D.,
Meda, P.,
Li, G.,
Halban, P. A.,
and Wollheim, C. B.
(1992)
Endocrinology
130,
167-178
32.
Janjic, D.,
and Asfari, M.
(1992)
J. Endocrinol.
132,
67-76
33.
Hoorens, A.,
Van de Casteele, M.,
Kloppel, G.,
and Pipeleers, D.
(1996)
J. Clin. Invest.
98,
1568-1574
34.
Fuchs, S. Y.,
Xie, B.,
Adler, V.,
Fried, V. A.,
Davis, R. J.,
and Ronai, Z.
(1997)
J. Biol. Chem.
272,
32163-32168
35.
Fuchs, S. Y.,
Dolan, L.,
Davis, R. J.,
and Ronai, Z.
(1996)
Oncogene
13,
1531-1535
36.
Derijard, B.,
Hibi, M.,
Wu, I. H.,
Barrett, T.,
Su, B.,
Deng, T.,
Karin, M.,
and Davis, R. J.
(1994)
Cell
76,
1025-1037
37.
Liu, X.,
Gupta, A. K.,
Corry, P. M.,
and Lee, Y. J.
(1997)
J. Biol. Chem.
272,
11690-11693
38.
Widmann, C.,
Gibson, S.,
Jarpe, M. B.,
and Johnson, G. L.
(1999)
Physiol. Rev.
79,
143-180
39.
Hohmeier, H. E.,
Thigpen, A.,
Tran, V. V.,
Davis, R.,
and Newgard, C. B.
(1998)
J. Clin. Invest.
101,
1811-1820
40.
Gupta, S.,
Barrett, T.,
Whitmarsh, A. J.,
Cavanagh, J.,
Sluss, H. K.,
Derijard, B.,
and Davis, R. J.
(1996)
EMBO J.
15,
2760-2770
41.
Yang, S. H.,
Whitmarsh, A. J.,
Davis, R. J.,
and Sharrocks, A. D.
(1998)
EMBO J.
17,
1740-1749
42.
Xia, Z.,
Dickens, M.,
Raingeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Y. Donath, J. Storling, L. A. Berchtold, N. Billestrup, and T. Mandrup-Poulsen Cytokines and {beta}-Cell Biology: from Concept to Clinical Translation Endocr. Rev., May 1, 2008; 29(3): 334 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ferdaoussi, S. Abdelli, J.-Y. Yang, M. Cornu, G. Niederhauser, D. Favre, C. Widmann, R. Regazzi, B. Thorens, G. Waeber, et al. Exendin-4 Protects {beta}-Cells From Interleukin-1{beta}-Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway Diabetes, May 1, 2008; 57(5): 1205 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. LaRosa and S. M. Downs Meiotic Induction by Heat Stress in Mouse Oocytes: Involvement of AMP-Activated Protein Kinase and MAPK Family Members Biol Reprod, March 1, 2007; 76(3): 476 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xie, F. Wang, W. Zhong, E. Puscheck, H. Shen, and D.A. Rappolee Shear Stress Induces Preimplantation Embryo Death That Is Delayed by the Zona Pellucida and Associated with Stress-Activated Protein Kinase-Mediated Apoptosis Biol Reprod, July 1, 2006; 75(1): 45 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xie, E.E. Puscheck, and D.A. Rappolee Effects of SAPK/JNK inhibitors on preimplantation mouse embryo development are influenced greatly by the amount of stress induced by the media Mol. Hum. Reprod., April 1, 2006; 12(4): 217 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Storling, S. V. Zaitsev, I. L. Kapelioukh, A. E. Karlsen, N. Billestrup, P.-O. Berggren, and T. Mandrup-Poulsen Calcium Has a Permissive Role in Interleukin-1{beta}-Induced c-Jun N-Terminal Kinase Activation in Insulin-Secreting Cells Endocrinology, July 1, 2005; 146(7): 3026 - 3036. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Storling, N. Allaman-Pillet, A. E. Karlsen, N. Billestrup, C. Bonny, and T. Mandrup-Poulsen Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells Endocrinology, April 1, 2005; 146(4): 1718 - 1726. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Aikin, D. Maysinger, and L. Rosenberg Cross-Talk between Phosphatidylinositol 3-Kinase/AKT and c-Jun NH2-Terminal Kinase Mediates Survival of Isolated Human Islets Endocrinology, October 1, 2004; 145(10): 4522 - 4531. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abderrahmani, G. Niederhauser, V. Plaisance, M.-E. Roehrich, V. Lenain, T. Coppola, R. Regazzi, and G. Waeber Complexin I regulates glucose-induced secretion in pancreatic {beta}-cells J. Cell Sci., May 1, 2004; 117(11): 2239 - 2247. [Abstract] |